Sinclair Pharmacy is expected to work in conjunction with Syntopix to develop a product. Should the collaboration result in a product that reaches commercialisation, financial gains from the sales will be shared between the two companies.
Stephen Jones, CEO of Syntopix, says: “We are delighted to be entering into this collaboration with Sinclair Pharmacy. I am very confident that its proprietary compound will be complemented and enhanced by some of the compounds that Syntopix has been identifying in this area over several years. We look forward to sharing exciting compounds and technical expertise with the intention of developing a health care product.”